The aim of the present study was to investigate the relationship between serum 25-hydroxyvitamin D levels and disease activity in patients with Systemic Lupus Erythematosus accompanied by renal involvement. In addition, the study evaluated correlations between 25-hydroxyvitamin D concentrations and various clinical as well as laboratory parameters, with the purpose of assessing its potential role as a biomarker of renal activity in lupus nephritis. A total of 128 individuals participated in the study and were divided into three groups: Group I included 53 patients with active lupus nephritis associated with SLE, Group II consisted of 57 patients with inactive lupus nephritis, and Group III comprised 30 apparently healthy subjects who served as controls. All participants underwent detailed history taking and comprehensive clinical examination. Disease activity was assessed using the SLEDAI-2K scoring system, and serum 25-hydroxyvitamin D levels were measured in all subjects. The study demonstrated that patients with SLE and lupus nephritis had significantly lower serum 25-hydroxyvitamin D levels compared with healthy controls. Moreover, individuals with active lupus nephritis showed the most pronounced decrease in vitamin D levels. These findings indicate that vitamin D insufficiency and deficiency are more common among patients with SLE/LN, especially during active stages of the disease. A significant association was observed between reduced serum 25-hydroxyvitamin D levels and clinical manifestations such as fatigue, photosensitivity, and hypertension. Regression analysis further identified lupus nephritis activity, photosensitivity, and elevated blood pressure as the major factors influencing serum 25-hydroxyvitamin D concentrations in patients with SLE.
Association Between Vitamin D Deficiency and Clinicolaboratory Activity of Kidney Involvement in Patients with SLE
DOI:
Keywords:
Abstract
References
Xipell, M., Lledó, G. M., Egan, A. C., Tamirou, F., Del Castillo, C. S., Rovira, J., Gómez-Puerta, J. A., García-Herrera, A., Cervera, R., Kronbichler, A., Jayne, D. R. W., Anders, H. J., Houssiau, F., Espinosa, G., & Quintana, L. F. (2023). From systemic lupus erythematosus to lupus nephritis: The evolving road to targeted therapies. Autoimmunity reviews, 22(10), 103404. https://doi.org/10.1016/j.autrev.2023.103404
Huang, J., An, Q., Ju, B. M., Zhang, J., Fan, P., He, L., & Wang, L. (2021). Role of 25-hydroxycalciferol/VDR nuclear translocation in down-regulation of NF-κB/NLRP3/caspase-1 axis in lupus nephritis. International immunopharmacology, 100, 108131. https://doi.org/10.1016/j.intimp.2021.108131
Palazzo, L., Lindblom, J., Mohan, C., & Parodis, I. (2022). Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature. Journal of clinical medicine, 11(19), 5759. https://doi.org/10.3390/jcm11195759
Chew, C., et al. (2021). Lower 25-hydroxycalciferol is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology (Oxford, England), 60(10), 4737–4747. https://doi.org/10.1093/rheumatology/keab090
Shankar, A. S., et al. (2021). 25-hydroxycalciferol metabolism in human kidney organoids. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 37(1), 190–193. https://doi.org/10.1093/ndt/gfab264
Ahn, S. S., Yoo, J., Jung, S. M., Song, J. J., Park, Y. B., & Lee, S. W. (2020). Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis. BMC nephrology, 21(1), 258. https://doi.org/10.1186/s12882-020-01915-5
Borchers, A. T., et al. (2010). The epidemiology of systemic lupus erythematosus. Autoimmunity reviews, 9(5), A277–A287. https://doi.org/10.1016/j.autrev.2009.12.008
Pérez-Ferro, M., Romero-Bueno, F. I., Serrano Del Castillo, C., Mahillo, I., Alvear, A., Largo, R., Herrero-Beaumont, G., & Sánchez-Pernaute, O. (2019). A subgroup of lupus patients with nephritis, innate T cell activation and low 25-hydroxycalciferol is identified by the enhancement of circulating MHC class I-related chain A. Clinical and experimental immunology, 196(3), 336–344. https://doi.org/10.1111/cei.13273
Hassanalilou, T., et al. (2017). Role of 25-hydroxycalciferol deficiency in systemic lupus erythematosus incidence and aggravation. Auto- immunity highlights, 9(1), 1. https://doi.org/10.1007/s13317-017-0101-x
Yap, K. S., & Morand, E. F. (2015). 25-hydroxycalciferol and systemic lupus erythematosus: continued evolution. International journal of rheumatic diseases, 18(2), 242–249. https://doi.org/10.1111/1756-185X.12489.
Terrier, B., et al. (2012). Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through 25-hydroxycalciferol supplementation. Arthritis research & therapy, 14(5), R221. https://doi.org/10.1186/ar4060
Ritterhouse, L. L., et al. (2011). 25-hydroxycalciferol deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Annals of the rheumatic diseases, 70(9), 1569–1574. https://doi.org/10.1136/ard.2010.148494
Hsu, S., Zelnick, L. R., Bansal, N., Brown, J., Denburg, M., Feldman, H. I., Ginsberg, C., Hoofnagle, A. N., Isakova, T., Leonard, M. B., Lidgard, B., Robinson-Cohen, C., Wolf, M., Xie, D., Kestenbaum, B. R., de Boer, I. H., & CRIC Study Investigators * (2023). 25-hydroxycalciferol Metabolites and Risk of Cardiovascular Disease in Chronic Kidney Disease: The CRIC Study. Journal of the American Heart Association, 12(14), e028561. https://doi.org/10.1161/JAHA.122.028561
Anders, H. J., et al. (2020). Lupus nephritis. Nature reviews. Disease primers, 6(1), 7. https://doi.org/10.1038/s41572-019-0141-9
Fu, S. M., et al. (2011). Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. Journal of autoimmunity, 37(2), 104–112. https://doi.org/10.1016/j.jaut.2011.05.004
Parikh, S. V., & Rovin, B. H. (2016). Current and Emerging Therapies for Lupus Nephritis. Journal of the American Society of Nephrology : JASN, 27(10), 2929–2939. https://doi.org/10.1681/ASN.2016040415
Borchers, A. T., et al. (2010). The geoepidemiology of systemic lupus erythematosus. Autoimmunity reviews, 9(5), A277–A287. https://doi.org/10.1016/j.autrev.2009.12.008
Yang, C. Y., et al. (2013). The implication of 25-hydroxycalciferol and autoimmunity: a comprehensive review. Clinical reviews in allergy & immunology, 45(2), 217–226. https://doi.org/10.1007/s12016-013-8361-3
Cusack, C., et al. (2008). Photoprotective behaviour and sunscreen use: impact on 25-hydroxycalciferol levels in cutaneous lupus erythematosus. Photodermatology, photoimmunology & photomedicine, 24(5), 260–267. https://doi.org/10.1111/j.1600-0781.2008.00373.x
Monticielo, O. A., et al. (2012). 25-hydroxycalciferol and polymorphisms of VDR gene in patients with systemic lupus erythematosus. Clinical rheumatology, 31(10), 1411–1421. https://doi.org/10.1007/s10067-012-2021-5
Anders, H. J., et al. (2020). Lupus nephritis. Nature reviews. Disease primers, 6(1), 7. https://doi.org/10.1038/s41572-019-0141-9
Abaza, N. M., et al. (2016). 25-hydroxycalciferol Deficiency in Egyptian Systemic Lupus Erythematosus Patients: How Prevalent and Does It Impact Disease Activity?. Integrative medicine insights, 11, 27–33. https://doi.org/10.4137/IMI.S40035
Gholamrezaei, A., et al. (2014). Sleep disorders in systemic lupus erythematosus. Does 25-hydroxycalciferol play a role?. Lupus, 23(10), 1054–1058. https://doi.org/10.1177/0961203314532563
Oren, Y., et al. (2010). 25-hydroxycalciferol insufficiency in a sunny environment: a demographic and seasonal analysis. The Israel Medical Association journal : IMAJ, 12(12), 751–756.
McMullan, C. J., Borgi, L., Curhan, G. C., Fisher, N., & Forman, J. P. (2017). The effect of 25-hydroxycalciferol on renin-angiotensin system activation and blood pressure: a randomized control trial. Journal of hypertension, 35(4), 822–829. https://doi.org/10.1097/HJH.0000000000001220
Schön, A., et al. (2021). Active 25-hydroxycalciferol is cardioprotective in experimental uraemia but not in children with CKD Stages 3-5. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 36(3), 442–451. https://doi.org/10.1093/ndt/gfaa227
Waldron, J. L., et al. (2013). 25-hydroxycalciferol: a negative acute phase reactant. Journal of clinical pathology, 66(7), 620–622. https://doi.org/10.1136/jclinpath-2012-201301
Munk, M. E., et al. (1999). Soluble tumor necrosis factor alpha receptors in sera from leprosy patients. Infection and immunity, 67(1), 423–425. https://doi.org/10.1128/IAI.67.1.423-425.1999
Chen, S., et al. (2007). Modulatory effects of 1,25-dihydroxy25-hydroxycalciferol3 on human B cell differentiation. Journal of immunology (Baltimore, Md. : 1950), 179(3), 1634–1647. https://doi.org/10.4049/jimmunol.179.3.1634
Mandal, M., et al. (2014). 25-hydroxycalciferol levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha. Arthritis research & therapy, 16(1), R49. https://doi.org/10.1186/ar4479
Nguyen, M. H., et al. (2018). 25-hydroxycalciferol in SLE: a role in pathogenesis and fatigue? A review of the literature. Lupus, 27(13), 2003–2011. https://doi.org/10.1177/0961203318796293
Феруза Тулкуновна, Х., Камола Маратовна , Д. ., & Хасанов, . А. . А. (2024). СЫВОРОТОЧНЫЙ ВИТАМИН D У ПАЦИЕНТОВ С СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКОЙ И ЕГО СВЯЗЬ С ЛЮПУС НЕФРИТОМ. Медицина и инновации, 10(2), 114–125.
Barnoyev Khabib Bobomurodovich, Shukurova Lobar Khusanovna, Khusankhodjaeva Feruza Tulkunovna ASSESSMENT OF RENAL FUNCTIONAL RESERVE ON THE BACKGROUND OF ANTIAGREGANT THERAPY IN STAGE II-III OF CHRONIC KIDNEY DISEASE // ORIENSS. 2021. No. 3. URL: https://cyberleninka.ru/article/n/surunkali-buyrak-kasalligining-ii-iii-bhoyilida-antiagregant-terapiya-fonida-buyrak-funksional-zaxirasini-baholash (date of access: 18.12.2025).
Daminova, . K. M. ., & Xusanxodjaeva , F. T. . (2022). СОВРЕМЕННЫЙ ПОДХОД К ВИТАМИНУ Д И СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКЕ. Медицина и инновации, 2(1).
Хусанходжаева, Ф., & Салямова, Ф. (2023). ЭФФЕКТИВНОСТЬ ВИТАМИНА Д У БОЛЬНЫХ С САХАРНЫМ ДИАБЕТОМ ПРИ ИНФЕКЦИИ МОЧЕВЫВОДЯЩИХ ПУТЕЙ.
Хусанходжаева, Ф. Т., & Даминова, К. М. (2023). LYUPUS NEFRIT RIVOJLANISHNING PATOGENETIK MEXANIZMLARI. MedUnion, 2(1), 261-270.
М. А, С., Ф. Э, С., & Ф. Т., Х. (2022). Нарушение Сердечного Ритма У Больных С Хронической Болезнь Почек Vст Как Предиктор Сердечно-Сосудистого Риск. Central Asian Journal of Medical and Natural Science, 3(2), 193-196. https://doi.org/10.51699/cajmns.v3i2.649
Хусанходжаева, Ф. Т., Салямова, Ф. Э., Ахмадалиева, Д. Т., & Кабилова, Г. А. (2022). Новый подход к лечению инфекций мочевых путей у больных сахарным диабетом 2 типа путем добавления витамина д. Uzbek Scholar Journal, 10, 407-417.
Erkinovna, S. F., Tulkunovna, X. F., Zoxiriddinovna, M. N., Iskandarovich, M. S., & Sanjarovna, I. M. (2022). Structural and functional features of the myocardium against the background of renal replacement therapy. International Journal of Medical Sciences And Clinical Research, 2(11), 01-07.
Хусанходжаева, Ф. Т. (2022). Оптимизация лечения инфекций мочевых путей у больных сахарным диабетом 2 типа путем добавления витамина Д. In Interdiscipline innovation and scientific research conference (Vol. 1, p. 3).